Poolbeg Pharma (LON:POLB) Stock Price Up 12.8% – Still a Buy?

Poolbeg Pharma PLC (LON:POLB)’s share price rose 12.8% during mid-day trading on Friday . The company traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.30 ($0.07). Approximately 1,229,697 shares traded hands during trading, a decline of 81% from the average daily volume of 6,431,729 shares. The stock had previously closed at GBX 4.70 ($0.06).

Analyst Ratings Changes

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, January 2nd.

Poolbeg Pharma Price Performance

The stock’s fifty day moving average is GBX 6.42 and its 200-day moving average is GBX 9.13. The stock has a market capitalization of £26.75 million, a PE ratio of -535.00 and a beta of 2.11.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.